Abstracts tagged "B cells and autoimmune diseases"

Abstract Number: 1122 • 2015 ACR/ARHP Annual Meeting
B Cell Phenotypic Changes in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Nan-Hua Chang¹, Babak Noamani², Dennisse Bonilla¹, Sindhu R. Johnson³, Larissa Lisnevskaia⁴, Earl Silverman⁵, Arthur Bookman¹ and Carolina Landolt-Marticorena¹, ¹University Health Network, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁴Lakeridge Health Services, Oshawa, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)+ but lack clinical symptoms. …
Abstract Number: 40 • 2013 ACR/ARHP Annual Meeting
Preclinical Characterization Of a Humanized Antagonistic Anti-CD40 Mab
Kerry Ralph, Amy Nicoletti, Eunice Musvasva, Susan Cannan, Susan VanTongeren, Diann Blanset, Scott Brodeur, Jennifer Ahlberg, Hua Li, Steve Fogal, Sudha Desai, Kathy O'Shea, Rachel Kroe-Barrett, Gerald Nabozny, Helen Wu, Gale Hansen, Keith Canada, Sanjaya Singh, Meera Ramanujam and Christine Grimaldi, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: CD40-CD40L interactions play a central role in T-B cell costimulation. Targeting this pathway has generated great interest; however early attempts to target CD40L failed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].